| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Pathology (HH, JFS, MYT) and Cardiothoracic Surgery (TSS, RSM, RJL), Allegheny General Hospital, and School of Dentistry (RJW), University of Pittsburgh, Pittsburgh, Pennsylvania.
Correspondence: Address correspondence and reprints requests to Dr. Rodney J. Landreneau, Dept. of Cardiothoracic Surgery, Allegheny General Hospital, 320 East North Ave., Pittsburgh, PA 15212; Fax: 412-359-6873.
BACKGROUND: Vascular endothelial growth factor (VEGF) plays an important role in tumor growth and metastasis. We investigated the prognostic significance of VEGF overexpression, intratumoral microvessel density (MVD), and angiolymphatic invasion in stage Ia-b non-small cell lung cancer (NSCLC).
METHODS: Eighty-five patients undergoing complete surgical resection of pathologic stage Ia-b NSCLC were evaluated. The mean and median clinical follow-up were 37.1 and 39.0 months (range, 30–44 months), respectively. Paraffin-embedded tumor specimens were stained with VEGF and CD31 (a specific endothelial marker) using immunohistochemical methods. VEGF staining was evaluated, by combining both percentage of positive tumor cells and staining intensity, as low (negative and < 20% of tumor cells showing weak positivity), or high (>20% of tumor cells showing strong positivity). CD31 staining was expressed as MVD per high power field at 400x magnification. Angiolymphatic invasion was expressed as either presence or absence.
RESULTS: Low VEGF expression was seen in 25 (29%) patients, and high VEGF expression was seen in 60 (71%) patients. The survival rate in patients with low VEGF expression was significantly higher (80%) than that in those with high VEGF expression (48%, P = .018). The mean MVD in the low VEGF group was 23.7 ± 5.7 vs. 34.4 ± 9.3 in the high VEGF group (P = .001). Patients with high MVD also had a significantly lower survival rate than did those with low MVD count (46% vs. 73%, P = .0053). Age, sex, tumor type, and tumor differentiation were not found to be associated with overall survival. The presence of angiolymphatic invasion and T2 stage (i.e., tumor size > 3 cm) were associated with decreased survival. High VEGF expression, tumor size, and angiolymphatic invasion emerged as three independent factors predicting worsening prognosis using multivariate analysis.
CONCLUSION: High VEGF expression within stage I NSCLC is closely associated with high intratumoral angiogenesis and poor prognosis. Immunohistochemical evaluation of T stage and VEGF expression along with examination of angiolymphatic invasion perioperatively may aid in predicting prognosis. Adjuvant therapies aimed at retarding tumor angiogenesis may be considered for stage I NSCLC patients with high VEGF levels.
Key Words: Vascular endothelial growth factor (VEGF)— • Microvessel density— • CD31— • Angiolymphatic invasion— • Non-small cell lung cancer.
This article has been cited by other articles:
 |
|
 |
|
  M. Benesch, M. Windelberg, W. Sauseng, V. Witt, G. Fleischhack, H. Lackner, H. Gadner, U. Bode, and C. Urban Compassionate use of bevacizumab (Avastin(R)) in children and young adults with refractory or recurrent solid tumors Ann. Onc., April 1, 2008; 19(4): 807 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Heist, R. Zhai, G. Liu, W. Zhou, X. Lin, L. Su, K. Asomaning, T. J. Lynch, J. C. Wain, and D. C. Christiani VEGF Polymorphisms and Survival in Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., February 20, 2008; 26(6): 856 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhai, G. Liu, W. Zhou, L. Su, R. S. Heist, T. J. Lynch, J. C. Wain, K. Asomaning, X. Lin, and D. C. Christiani Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non-Small Cell Lung Cancer Clin. Cancer Res., January 15, 2008; 14(2): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Giaccone The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Enatsu, A. Iwasaki, T. Shirakusa, M. Hamasaki, K. Nabeshima, H. Iwasaki, M. Kuroki, and M. Kuroki Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 891 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Xu, D. M. Cochran, R. T. Tong, F. Winkler, S. Kashiwagi, R. K. Jain, and D. Fukumura Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res., April 15, 2006; 66(8): 3971 - 3977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T C Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, and G Tonini Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer J. Clin. Pathol., June 1, 2004; 57(6): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fujimoto, T. Abe, N. L. Muller, H. Terasaki, S. Kato, J. Sadohara, R. Kono, O. Edamitsu, T. Ishitake, A. Hayashi, et al. Small Peripheral Pulmonary Carcinomas Evaluated with Dynamic MR Imaging: Correlation with Tumor Vascularity and Prognosis Radiology, June 1, 2003; 227(3): 786 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Laack, A. Kohler, C. Kugler, T. Dierlamm, C. Knuffmann, G. Vohwinkel, A. Niestroy, N. Dahlmann, A. Peters, J. Berger, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer Ann. Onc., October 1, 2002; 13(10): 1550 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Rice and C M Quinn Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast J. Clin. Pathol., August 1, 2002; 55(8): 569 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]
|
|
|
|
 |
|
 C.S. Brock and S.M. Lee Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Eur. Respir. J., March 1, 2002; 19(3): 557 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fosslien Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 325 - 348. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
